# Relief Therapeutics Holding

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/relief-therapeutics-holding

- Industry: Biotechnology
- Headquarters: Geneva, Switzerland
- Website: www.relieftherapeutics.com
- Latest round: Series A (May 24, 2016)
- Investors on record: 1

## About

Relief Therapeutics Holding AG is a Swiss-based biopharmaceutical company focused on developing innovative therapies for patients with specialty, rare, and ultra-rare diseases.Founded in 2013 and headquartered in Geneva, Switzerland, Relief Therapeutics aims to create solutions for conditions lacking effective treatments. The company has undergone strategic pivots to enhance its drug pipeline and currently has three funding rounds, with the most recent being a PIPE round in July 2021, raising CHF 15.000 mn. The CEO, Michelle Lock, leads the company in its mission to address unmet medical needs.Relief Therapeutics specializes in developing and commercializing innovative, patent-protected therapies aimed at addressing the needs of patients with specialty, rare, and ultra-rare diseases. The company’s core offerings focus on providing effective treatments for conditions that currently lack adequate therapeutic solutions. Their products cater to various therapeutic areas, including rare genetic disorders and niche disease categories, and are distributed through selected partnerships in multiple markets, including Europe and North America, ensuring access for patients and healthcare providers.In the most recent fiscal year of 2022, Relief Therapeutics reported a revenue of CHF 6,373,873.4, with an EBITDA of CHF -50,500,447.1, reflecting the ongoing investment in their therapeutic developments.Relief Therapeutics plans to utilize the CHF 15.000 mn raised in PIPE funding from July 2021 to expand its drug pipeline and acquire additional assets, alongside general corporate purposes. The company is actively developing new products aimed at addressing specialty disease conditions and seeks to enter new markets, particularly in Europe and North America, focusing on enhancing its distribution networks by the end of 2023.

## Funding rounds

- Series A, May 24, 2016 — Global Emerging Markets

## Investors

- Global Emerging Markets (https://capitalatlas.ai/funds/global-emerging-markets) — Series A